Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

Inclusion Criteria: * Recurrent grade 3 or 4 glioma, including astrocytoma, oligodendroglioma or mixed glioma with histologic confirmation at initial diagnosis or recurrence * Candidate for gross total or subtotal resection * Absolute neutrophil count (ANC) \>= 1500/uL * Platelets (PLT) \>= 100,000/uL * Total bilirubin =\< 1.5 x upper normal limit (ULN) * Aspartate aminotransferase (AST) =\< 2 x ULN * Creatinine =\< 2.0 x ULN * Hemoglobin (Hgb) \>= 9.0 gm/dL * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) =\< 1.3 x ULN * Ability to provide informed consent * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * Anti-measles virus immunity as demonstrated by immunoglobulin G (IgG) anti-measles antibody levels of \>= 1.1 EU/ml as determined by enzyme immunoassay * Normal serum CEA levels (\< 3 ng/ml) at the time of registration * Willing to provide biologic specimens as required by the protocol * Negative serum pregnancy test done =\< 7 days prior to registration (for women of childbearing potential only) Exclusion Criteria: * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception * Active infection =\< 5 days prior to registration * History of tuberculosis or history of purified protein derivative (PPD) positivity * Any of the following therapies: * Chemotherapy =\< 4 weeks prior to registration (6 wks for nitrosourea-based chemotherapy) * Immunotherapy =\< 4 weeks prior to registration * Biologic therapy =\< 4 weeks prior to registration * Bevacizumab =\< 12 weeks prior to registration * Non-cytotoxic antitumor drugs, i.e., small molecule cell cycle inhibitors =\< 2 weeks prior to registration * Radiation therapy =\< 6 weeks prior to registration * Any viral or gene therapy prior to registration * Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment * New York Heart Association classification III or IV * Requiring blood product support * Inadequate seizure control * Expected communication between ventricles and resection cavity as a result of surgery * Human immunodeficiency virus (HIV)-positive test result, or history of other immunodeficiency * History of organ transplantation * History of chronic hepatitis B or C * Other concurrent chemotherapy, immunotherapy, radiotherapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration \[FDA\]-approved indication and in the context of a research investigation) * Exposure to household contacts =\< 15 months old or household contact with known immunodeficiency * Allergy to measles vaccine or history of severe reaction to prior measles vaccination